Invitrogen

CD263 (TRAIL-R3) Monoclonal Antibody (DJR3), PE, eBioscience™

CD263 (TRAIL-R3) Antibody in Flow Cytometry (Flow)

FIGURE: 1 / 1

CD263 (TRAIL-R3) Antibody (12-6238-42) in Flow

Staining of human CD263-transfected cells with Mouse IgG1 kappa Isotype Control PE (Product # 12-4714-81) (open histogram) or Anti-Human CD263 (TRAIL-R3) PE (filled histogram). Total viable cells were used for analysis.

Product Image Gallery

Product Details

12-6238-42

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (1 µg)/test

View 5 publications 5 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

DJR3

Conjugate

PE PE PE

Excitation/Emission Max

565/576 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_11041519

Product Specific Information

Description: The DJR3 monoclonal antibody reacts with human Decoy receptor 1 (DcR1), a glycophospholipid-anchored cell surface protein also known as TRAIL-R3, TRID, and LIT. DcR1 has an extracellular TRAIL binding domain and lacks the cytoplasmic death domain (DD) shared by several members of the TNF receptor superfamily. DcR1, along with DcR2, protects cells from TRAIL-mediated cytotoxicity. DcR1 binds to TRAIL and inhibits binding of TRAIL to DR4 or DR5. DcR1 is expressed broadly in many normal tissues at low level, but not in most tumors. Overexpression of DcR1 attenuates TRAIL-induced apoptosis.

Applications Reported: The DJR3 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This DJR3 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells and human DcR1-transfected cells. This can be used at 5 µL (1 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

TRAIL-R3 (CD263) is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

How to use the Panel Builder

Watch the video to learn how to use the Invitrogen Flow Cytometry Panel Builder to build your next flow cytometry panel in 5 easy steps.

Product References

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

PloS one

Turner A,Li LC,Pilli T,Qian L,Wiley EL,Setty S,Christov K,Ganesh L,Maker AV,Li P,Kanteti P,Das Gupta TK,Prabhakar BS

12-6238 was used in Flow cytometry/Cell sorting to investigate how strategies to decrease MADD expression in breast cancer may be utilised to increase tumour cell sensitivity to TRAIL and doxorubicin induced apoptosis.

Wed Aug 28 00:00:00 EDT 2013

Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.

Blood

Hanada K,Wang QJ,Inozume T,Yang JC

12-6238 was used in Flow cytometry/Cell sorting to elucidate the nature of the ligand for a α/β TCR that lyses renal cell carcinoma cells regardless of MHC type.

Thu May 05 00:00:00 EDT 2011

TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.

BMC musculoskeletal disorders

Bisgin A,Terzioglu E,Aydin C,Yoldas B,Yazisiz V,Balci N,Bagci H,Gorczynski RM,Akdis CA,Sanlioglu S

12-6238 was used in Flow cytometry/Cell sorting to study disease severity in patients with rheumatoid arthritis via TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells.

Fri Aug 27 00:00:00 EDT 2010

CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.

Cancer research

Lin YD,Chen S,Yue P,Zou W,Benbrook DM,Liu S,Le TC,Berlin KD,Khuri FR,Sun SY

12-6238 was used in Flow cytometry/Cell sorting to reveal a novel mechanism underlying flexible heteroarotinoid-induced apoptosis that involves induction of death receptor 5.

Tue Jul 01 00:00:00 EDT 2008

The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.

The Journal of biological chemistry

Sun SY,Liu X,Zou W,Yue P,Marcus AI,Khuri FR

12-6238 was used in Flow cytometry/Cell sorting to investigate the underlying mechanism by which farnesyltransferase inhibitors cause growth arrest or apoptosis in cancer cells, showing that it induces expression of death receptor 5.

Fri Jun 29 00:00:00 EDT 2007

Bioinformatics

Protein Aliases: Antagonist decoy receptor for TRAIL/Apo-2L; CD263; cytotoxic TRAIL receptor-3; DcR1; Decoy receptor 1; Decoy TRAIL receptor without death domain; Lymphocyte inhibitor of TRAIL; MGC149501; MGC149502; TNF-related apoptosis-inducing ligand receptor 3; TRAIL receptor 3; TRAIL receptor without an intracellular domain; Tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain

View more View less

Gene Aliases: CD263; DCR1; DCR1-TNFR; LIT; TNFRSF10C; TRAIL-R3; TRAILR3; TRID; UNQ321/PRO366

View more View less

UniProt ID: (Human) O14798

View more View less

Entrez Gene ID: (Human) 8794

View more View less

Function(s)

transmembrane signaling receptor activity tumor necrosis factor-activated receptor activity TRAIL binding transmembrane signal receptor

Process(es)

inflammatory response immune response signal transduction multicellular organism development extrinsic apoptotic signaling pathway via death domain receptors response to lipopolysaccharide tumor necrosis factor-mediated signaling pathway regulation of cell proliferation regulation of apoptotic process

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

CD263 (TRAIL-R3) Monoclonal Antibody (DJR3), PE, eBioscience™

CD263 (TRAIL-R3) Antibody (12-6238-42) in Flow

Product Details

12-6238-42

Flow Cytometry (Flow)

Species Reactivity

Published species

Host/Isotype

Recommended Isotype Control

Class

Type

Clone

Conjugate

Excitation/Emission Max

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

How to use the Panel Builder

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!